Skip to Content

ApoGen Receives $7 Million Investment for Cancer Therapy

Researcher with pipettes and petri dishes

A University of Minnesota startup recently attracted a major investment to support continued development of drug therapies that make cancer treatments more effective.

ApoGen Biotechnologies Inc., launched in October 2014, announced last month that it had received $7 million from life science investment firm Accelerator Corporation to continue developing a new class of drugs that slows the evolution of cancer cells and to move these treatments toward clinical trials. ApoGen is based on discoveries by two U researchers: Reuben Harris, Ph.D., professor of biochemistry, molecular biology and biophysics; and Daniel Harki, Ph.D., assistant professor of medicinal chemistry. John Santini Jr., Ph.D., is the company’s president and CEO.

Cancer therapies often become less effective over time as cancer cells become resistant to treatment. ApoGen’s drugs are designed to block a key enzyme that causes drug resistance, potentially making current and future treatments more effective.

“I have been working with Drs. Harris and Harki to move ApoGen’s science toward clinical and commercial development, and I am thrilled to now partner with Accelerator Corporation,” Santini said in a press release. “We believe that we have assembled the ideal team to advance our therapeutic technologies to slow or stop tumor evolution, which has the potential to yield a significant clinical impact for cancer patients.”

Russ Straate, associate director of the Venture Center, part of the U’s Office for Technology Commercialization, said Accelerator Corporation’s investment marks a milestone for ApoGen.

“For a startup that aims to develop a therapy based on innovative research and bring it to market, an investment like this is crucial,” Straate said. “This funding will help ApoGen in its next steps toward clinical trials and move it closer to the ultimate goal of getting this unique cancer therapy into the hands of those who can benefit from it.”

For more on the Accelerator Corporation’s investment in ApoGen, see the College of Biological Sciences blog.

Kevin Coss

Kevin Coss

Kevin is a writer and public relations associate with the Office of the Vice President for Research.

Latest Blog Posts

Scientist works in lab with a petri dish

The University of Minnesota’s Clinical and Translational Science Institute (CTSI) was recently awarded one of the two largest federal grants the University has ever received: $42.6 million in renewed funding from the National Institutes of Health (NIH) through the National Center for Advancing Translational Sciences' Clinical and Translational Science Award (CTSA) program.

Read More
Lita Stantic

Ana Forcinito explores how women filmmakers in Argentina have used cinema to express thoughts, ideas, and emotions normally hidden in a patriarchal society.

Read More
Gerlad Vitec

Industry experts and investors gathered this week for the Neuroscience Technology Showcase, which highlighted technologies that hold the potential to more effectively treat a wide range of neurological disorders.

Read More
Test tubes with green liquid and empty flasks on a laboratory table

The Minnesota Cancer Clinical Trials Network, formed through the state-funded MnDRIVE initiative, will expand cancer clinical trial access across Minnesota. 

Read More
Categories: